Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide

Tomoko Ichiki, Nina Dzhoyashvili, John C Jr. Burnett

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure.

Original languageEnglish (US)
JournalInternational Journal of Cardiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Natriuretic Peptides
Peptide Receptors
Heart Failure
C-Type Natriuretic Peptide
Guanylate Cyclase
Hypotension
Therapeutics
Kidney
cenderitide

Keywords

  • Designer natriuretic peptide
  • Drug development
  • Heart failure
  • Natriuretic peptide
  • Receptors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{ca2df34e925c4e948c78f0d6f6160347,
title = "Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide",
abstract = "Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure.",
keywords = "Designer natriuretic peptide, Drug development, Heart failure, Natriuretic peptide, Receptors",
author = "Tomoko Ichiki and Nina Dzhoyashvili and Burnett, {John C Jr.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ijcard.2018.06.002",
language = "English (US)",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Natriuretic peptide based therapeutics for heart failure

T2 - Cenderitide: A novel first-in-class designer natriuretic peptide

AU - Ichiki, Tomoko

AU - Dzhoyashvili, Nina

AU - Burnett, John C Jr.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure.

AB - Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure.

KW - Designer natriuretic peptide

KW - Drug development

KW - Heart failure

KW - Natriuretic peptide

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=85048896146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048896146&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2018.06.002

DO - 10.1016/j.ijcard.2018.06.002

M3 - Article

C2 - 29941213

AN - SCOPUS:85048896146

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -